ns 1619 has been researched along with Leukemia, Lymphoblastic, Acute, T Cell in 1 studies
NS 1619: structure given in first source
NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silic-Benussi, M | 1 |
| Scattolin, G | 1 |
| Cavallari, I | 1 |
| Minuzzo, S | 1 |
| Del Bianco, P | 1 |
| Francescato, S | 1 |
| Basso, G | 1 |
| Indraccolo, S | 1 |
| D'Agostino, DM | 1 |
| Ciminale, V | 1 |
1 other study available for ns 1619 and Leukemia, Lymphoblastic, Acute, T Cell
| Article | Year |
|---|---|
Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis.
Topics: Animals; Apoptosis; Benzimidazoles; Dehydroepiandrosterone; GTP Phosphohydrolases; Humans; Metalloen | 2018 |